Article
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants.
Science (New York, N.Y.) - 13 Aug 2021
Wang Lingshu, Zhou Tongqing, Zhang Yi, Yang Eun Sung, Schramm Chaim A, Shi Wei, Pegu Amarendra, Oloniniyi Olamide K, Henry Amy R, Darko Samuel, Narpala Sandeep R, Hatcher Christian, Martinez David R, Tsybovsky Yaroslav, Phung Emily, Abiona Olubukola M, Antia Avan, Cale Evan M, Chang Lauren A, Choe Misook, Corbett Kizzmekia S, Davis Rachel L, DiPiazza Anthony T, Gordon Ingelise J, Hait Sabrina Helmold, Hermanus Tandile, Kgagudi Prudence, Laboune Farida, Leung Kwanyee, Liu Tracy, Mason Rosemarie D, Nazzari Alexandra F, Novik Laura, O'Connell Sarah, O'Dell Sijy, Olia Adam S, Schmidt Stephen D, Stephens Tyler, Stringham Christopher D, Talana Chloe Adrienna, Teng I-Ting, Wagner Danielle A, Widge Alicia T, Zhang Baoshan, Roederer Mario, Ledgerwood Julie E, Ruckwardt Tracy J, Gaudinski Martin R, Moore Penny L, Doria-Rose Nicole A, Baric Ralph S, Graham Barney S, McDermott Adrian B, Douek Daniel C, Kwong Peter D, Mascola John R, Sullivan Nancy J, Misasi John
Abstract excerpt
The emergence of highly transmissible SARS-CoV-2 variants of concern (VOCs) that are resistant to therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies. We identified four receptor binding domain-targeting antibodies from three early-outbreak convalescent donors with potent neutralizing activity against 23 variants, including the B.1.1.7, B.1.351, P.1, B.1.429,...
Read the complete abstract on PubMed